Hepatocellular Carcinoma (HCC) – Richard Finn, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO GI 2019

Hepatocellular Carcinoma (HCC) – Richard Finn, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO GI 2019

Wednesday February 13, 2019

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Richard Finn, MD, Professor of Medicine at the Geffen School of Medicine, UCLA, discuss hepatocellular carcinoma (HCC) clinical highlights from ASCO GI 2019

Non Small Cell Lung Cancer (NSCLC) – Edward Garon, MD, and Robert Figlin, MD, discuss promising agents in development for the management of NSCLC from ASCO20

Thursday June 11, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Edward Garon, MD, Director of Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, Associate Professor of Medicine, David Geffen School of Medicine, UCLA, discuss promising agents in development for the management of NSCLC from ASCO20

Waldenstrom macroglobulinemia – Constantine Tam, MD, and Robert Figlin, MD, discuss recent clinical advances in the treatment of Waldenstrom macroglobulinemia from ASCO20

Monday June 8, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Constantine Tam, MD, Haematologist and Disease Group Lead, Low Grade Lymphoma and Chronic Lymphocytic Leukemia, Peter MacCallum Cancer Centre, discuss the progress in Waldenstrom macroglobulinemia from ASCO20

Featured Videos

Shaji Kumar, MD, shares the design and outcomes of the CARTITUDE-1 trial regarding multiple myeloma

Dana Chase, MD, FACOG, summarizes the outcomes of the NRG-GY004 phase III study in ovarian cancer

Nancy Lin, MD, considers whether the results of the HER2CLIMB study will become a new care standard